Latest From AntiCancer Inc.
A US district court has granted a motion filed by Sun Pharma for partial summary judgement in its three-year battle over Lilly's Gemzar (gemcitabine HCl for injection) – invalidating Lilly's method-of-use patent (the '826 patent), which includes paediatric exclusivity and is set to expire in May 2013.
The Delhi High Court has indicted Bayer for attempting to use "speculative" litigation in India, in a case concerning Cipla's application to introduce a generic version of Bayer's anticancer Nexavar (sorafenib tosylate).
The High Court in Delhi, India has indicted Bayer for "speculative" litigation in a case concerning Cipla's marketing application for a generic version of the anticancer sorafenib tosylate.
Amgen's EGFR-targeted human monoclonal antibody, Vectibix (panitumumab), met one of its co-primary endpoints, progression-free survival (PFS), but not the other, overall survival, in patients with KRAS wild-type metastatic colorectal cancer (mCRC) in the pivotal Phase III "181" trial testing it as second-line therapy.
- In Vitro Diagnostics
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- AntiCancer Inc.
- Senior Management
Robert M Hoffman, PhD, Pres. & CEO
Charlene M Cooper, VP, COO
- Contact Info
Phone: (858) 654-2555
7917 Ostrow St.
San Diego, CA 92111
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.